Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Sep;29(5):390-400.
doi: 10.1111/ajad.13068.

Addiction Psychiatry and Addiction Medicine: The Evolution of Addiction Physician Specialists

Affiliations
Review

Addiction Psychiatry and Addiction Medicine: The Evolution of Addiction Physician Specialists

Edward V Nunes et al. Am J Addict. 2020 Sep.

Abstract

Addiction Psychiatry and Addiction Medicine are two physician subspecialities recognized by the American Board of Medical Specialties (ABMS) that focus on providing care for patients with substance use disorders. Their shared and distinct historical roots are reviewed, and their respective ABMS board examination content areas and Accreditation Council on Graduate Medical Education (ACGME) fellowship training program requirements are compared. Addiction Psychiatry, a subspecialty under the American Board of Psychiatry and Neurology, began certifying diplomates in 1993, currently has 1202 active diplomates, and certifies around 150 diplomates every 2 years through 50 ACGME-accredited fellowships. Addiction Medicine, a subspecialty under the American Board of Preventive Medicine, began certifying diplomates in 2018, has 2604 diplomates with more expected before the practice pathway closes (anticipated in 2021), after which a fellowship training becomes required. Currently there are 78 accredited Addiction Medicine fellowships and more under development. The fields display substantial overlap between their respective examination content areas and fellowship training requirements, covering similar knowledge and skills for evaluation and treatment of substance use disorders and psychiatric and medical comorbidities across the full range of clinical settings, from general medical to addiction specialty settings. Key differences include that Addiction Psychiatry is open only to Board-certified psychiatrists and places extra emphasis on psychotherapeutic and psychopharmacological management strategies. Addiction Medicine is open to any ABMS primary specialty, including psychiatry. Opportunities for collaboration are discussed as both fields pursue the common goal of providing a well-trained workforce of physicians to meet the public health challenge presented by addiction. (Am J Addict 2020;00:00-00).

PubMed Disclaimer

Similar articles

Cited by

References

REFERENCES

    1. Grimm CA. Geographic Disparities Affect Access to Buprenorphine Services for Opioid Use Disorder. Washington, DC: Office of the Inspector General; 2020:39. https://oig.hhs.gov/oei/reports/oei-12-17-00240.pdf
    1. Substance Abuse and Mental Health Services Administration. Key substance use and mental health indicators in the United States: results from the 2018 National Survey on Drug Use and Health (HHS Publication No. PEP19-5068, NSDUH Series H-54). Rockville, MD: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration; 2019. Retrieved from https://www.samhsa.gov/data/
    1. Kunz K, White W. Addiction Medicine in America: its birth, early history and current status 1750-2018. In: Miller SC, Fiellin DA, Rosenthal RN, Saitz R, American Society of Addiction Medicine, eds. The ASAM Principles of Addiction Medicine, 6th ed. Philadelphia, PA: Wolters Kluwer; 2019:365-375.
    1. Galanter M, Dermatis H, Calabrese D. Residencies in addiction psychiatry: 1990 to 2000, a decade of progress. Am J Addict. 2002;11:192-199. https://doi.org/10.1080/10550490290087956
    1. Freed CR. Addiction Medicine and Addiction Psychiatry in America: Commonalities in the medical treatment of addiction. Contemp Drug Probl. 2010;37:139-163. https://doi.org/10.1177/009145091003700107

LinkOut - more resources